GSK plc (GLAXF)
USD 20.85
(0.63%)
USD 20.85
(0.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.08 Billion GBP | 5.47% |
| 2022 | 8.6 Billion GBP | 0.22% |
| 2021 | 6.48 Billion GBP | 3.56% |
| 2020 | 8.06 Billion GBP | -16.24% |
| 2019 | 10.12 Billion GBP | 37.66% |
| 2018 | 7.35 Billion GBP | 2.97% |
| 2017 | 7.14 Billion GBP | 57.54% |
| 2016 | 4.53 Billion GBP | -63.13% |
| 2015 | 12.3 Billion GBP | 115.03% |
| 2014 | 5.72 Billion GBP | -33.06% |
| 2013 | 8.54 Billion GBP | -0.44% |
| 2012 | 8.58 Billion GBP | -10.47% |
| 2011 | 9.58 Billion GBP | 60.62% |
| 2010 | 5.97 Billion GBP | -38.87% |
| 2009 | 9.76 Billion GBP | 12.46% |
| 2008 | 8.68 Billion GBP | -3.78% |
| 2007 | 9.02 Billion GBP | -1.04% |
| 2006 | 9.12 Billion GBP | 10.07% |
| 2005 | 8.28 Billion GBP | 14.78% |
| 2004 | 7.21 Billion GBP | -4.19% |
| 2003 | 7.53 Billion GBP | -0.42% |
| 2002 | 7.56 Billion GBP | 12.74% |
| 2001 | 6.71 Billion GBP | 15.72% |
| 2000 | 5.8 Billion GBP | 71.45% |
| 1999 | 3.38 Billion GBP | 5.65% |
| 1998 | 3.2 Billion GBP | -4.73% |
| 1997 | 3.36 Billion GBP | -7.79% |
| 1996 | 3.64 Billion GBP | -18.0% |
| 1995 | 4.44 Billion GBP | 106.07% |
| 1994 | 2.15 Billion GBP | 10.56% |
| 1993 | 2.15 Billion GBP | 15.65% |
| 1992 | 1.68 Billion GBP | 11.8% |
| 1991 | 1.5 Billion GBP | 11.94% |
| 1990 | 1.34 Billion GBP | 19.82% |
| 1989 | 1.12 Billion GBP | 21.49% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.62 Billion GBP | 11.5% |
| 2024 Q1 | 2.53 Billion GBP | -7.17% |
| 2024 Q3 | 1.17 Billion GBP | -49.26% |
| 2023 FY | - GBP | 5.47% |
| 2023 Q4 | 2.23 Billion GBP | -12.62% |
| 2023 Q1 | 2.74 Billion GBP | 44.99% |
| 2023 Q2 | 2.62 Billion GBP | -4.55% |
| 2023 Q3 | 2.55 Billion GBP | -2.74% |
| 2022 Q3 | 2.16 Billion GBP | 25.25% |
| 2022 Q1 | 3.51 Billion GBP | 291.75% |
| 2022 Q2 | 1.73 Billion GBP | -50.74% |
| 2022 FY | - GBP | 0.22% |
| 2022 Q4 | 1.89 Billion GBP | -12.55% |
| 2021 Q1 | 2.08 Billion GBP | 96.23% |
| 2021 Q4 | 897 Million GBP | -69.43% |
| 2021 Q3 | 2.93 Billion GBP | 24.22% |
| 2021 Q2 | 2.36 Billion GBP | 13.56% |
| 2021 FY | - GBP | 3.56% |
| 2020 FY | - GBP | -16.24% |
| 2020 Q4 | 1.06 Billion GBP | -57.77% |
| 2020 Q1 | 2.25 Billion GBP | 17.79% |
| 2020 Q3 | 2.51 Billion GBP | -12.54% |
| 2020 Q2 | 2.87 Billion GBP | 27.1% |
| 2019 Q3 | 2.7 Billion GBP | 18.97% |
| 2019 Q1 | 2.7 Billion GBP | 70.69% |
| 2019 Q4 | 1.91 Billion GBP | -29.24% |
| 2019 Q2 | 2.27 Billion GBP | -15.73% |
| 2019 FY | - GBP | 37.66% |
| 2018 Q4 | 1.58 Billion GBP | -34.88% |
| 2018 Q2 | 1 Billion GBP | -42.59% |
| 2018 Q1 | 1.74 Billion GBP | 229.62% |
| 2018 FY | - GBP | 2.97% |
| 2018 Q3 | 2.43 Billion GBP | 142.37% |
| 2017 Q1 | 2.07 Billion GBP | 236.04% |
| 2017 Q3 | 2.58 Billion GBP | 138.76% |
| 2017 Q2 | 1.08 Billion GBP | -47.78% |
| 2017 FY | - GBP | 57.54% |
| 2017 Q4 | 530 Million GBP | -79.47% |
| 2016 Q1 | 1.29 Billion GBP | 695.87% |
| 2016 Q2 | 266 Million GBP | -79.52% |
| 2016 FY | - GBP | -63.13% |
| 2016 Q3 | 1.64 Billion GBP | 518.05% |
| 2016 Q4 | 616 Million GBP | -62.53% |
| 2015 Q3 | 1.27 Billion GBP | 19.25% |
| 2015 Q2 | 1.07 Billion GBP | -88.92% |
| 2015 Q1 | 9.65 Billion GBP | 1241.39% |
| 2015 Q4 | -218 Million GBP | -117.08% |
| 2015 FY | - GBP | 115.03% |
| 2014 Q3 | 1.1 Billion GBP | -27.96% |
| 2014 Q4 | 720 Million GBP | -35.02% |
| 2014 Q2 | 1.53 Billion GBP | -7.24% |
| 2014 Q1 | 1.65 Billion GBP | -32.85% |
| 2014 FY | - GBP | -33.06% |
| 2013 Q4 | 2.46 Billion GBP | 6.24% |
| 2013 Q3 | 2.32 Billion GBP | 16.08% |
| 2013 Q2 | 2 Billion GBP | -7.87% |
| 2013 Q1 | 2.17 Billion GBP | 10.03% |
| 2013 FY | - GBP | -0.44% |
| 2012 FY | - GBP | -10.47% |
| 2012 Q4 | 1.97 Billion GBP | 0.0% |
| 2012 Q3 | 1.97 Billion GBP | -0.75% |
| 2012 Q2 | 1.99 Billion GBP | -15.43% |
| 2012 Q1 | 2.35 Billion GBP | 23.58% |
| 2011 FY | - GBP | 60.62% |
| 2011 Q2 | 2.2 Billion GBP | 16.97% |
| 2011 Q3 | 2.61 Billion GBP | 18.68% |
| 2011 Q1 | 1.88 Billion GBP | 2549.35% |
| 2011 Q4 | 1.9 Billion GBP | -27.27% |
| 2010 FY | - GBP | -38.87% |
| 2010 Q3 | 2.54 Billion GBP | 378.57% |
| 2010 Q4 | -77 Million GBP | -103.02% |
| 2010 Q1 | 2.37 Billion GBP | -14.03% |
| 2010 Q2 | 532 Million GBP | -77.63% |
| 2009 Q3 | 2.57 Billion GBP | 8.16% |
| 2009 FY | - GBP | 12.46% |
| 2009 Q4 | 2.76 Billion GBP | 7.58% |
| 2009 Q1 | 2.34 Billion GBP | 26.17% |
| 2009 Q2 | 2.37 Billion GBP | 1.45% |
| 2008 FY | - GBP | -3.78% |
| 2008 Q1 | 2.43 Billion GBP | 32.96% |
| 2008 Q4 | 1.85 Billion GBP | -13.63% |
| 2008 Q3 | 2.15 Billion GBP | -7.45% |
| 2008 Q2 | 2.32 Billion GBP | -4.76% |
| 2007 Q2 | 2.21 Billion GBP | -11.9% |
| 2007 Q1 | 2.51 Billion GBP | 101.25% |
| 2007 Q3 | 396 Million GBP | -82.11% |
| 2007 FY | - GBP | -1.04% |
| 2007 Q4 | 1.83 Billion GBP | 363.24% |
| 2006 Q2 | 2.2 Billion GBP | -11.52% |
| 2006 Q4 | 1.24 Billion GBP | -48.1% |
| 2006 Q1 | 2.49 Billion GBP | 147.33% |
| 2006 Q3 | 2.4 Billion GBP | 9.04% |
| 2006 FY | - GBP | 10.07% |
| 2005 Q2 | 1.96 Billion GBP | 3.01% |
| 2005 Q3 | 2.11 Billion GBP | 7.87% |
| 2005 Q4 | -5.26 Billion GBP | -348.68% |
| 2005 FY | - GBP | 14.78% |
| 2005 Q1 | 1.9 Billion GBP | 49.94% |
| 2004 FY | - GBP | -4.19% |
| 2004 Q4 | 1.27 Billion GBP | -28.57% |
| 2004 Q2 | 1.94 Billion GBP | 6.81% |
| 2004 Q3 | 1.78 Billion GBP | -8.41% |
| 2004 Q1 | 1.82 Billion GBP | 47.23% |
| 2003 Q1 | 1.86 Billion GBP | -12.56% |
| 2003 FY | - GBP | -0.42% |
| 2003 Q4 | 1.19 Billion GBP | -34.31% |
| 2003 Q3 | 2.07 Billion GBP | -18.11% |
| 2003 Q2 | 2.1 Billion GBP | 23.52% |
| 2002 Q4 | 1.62 Billion GBP | 28.19% |
| 2002 Q1 | 1.71 Billion GBP | 6.92% |
| 2002 FY | - GBP | 12.74% |
| 2002 Q2 | 1.82 Billion GBP | 7.41% |
| 2002 Q3 | 1.38 Billion GBP | -17.62% |
| 2001 Q4 | 3.12 Billion GBP | 9.73% |
| 2001 FY | - GBP | 15.72% |
| 2001 Q1 | 1.2 Billion GBP | 25.91% |
| 2001 Q2 | 1.64 Billion GBP | 15.95% |
| 2001 Q3 | 1.59 Billion GBP | -11.31% |
| 2000 FY | - GBP | 71.45% |
| 2000 Q1 | 1.35 Billion GBP | 140.55% |
| 2000 Q2 | 1.3 Billion GBP | -1.22% |
| 2000 Q3 | 1.21 Billion GBP | -11.57% |
| 2000 Q4 | 1.23 Billion GBP | 1.65% |
| 1999 Q3 | 2.27 Billion GBP | 223.95% |
| 1999 Q2 | 762.06 Million GBP | -65.08% |
| 1999 FY | - GBP | 5.65% |
| 1999 Q1 | 2.01 Billion GBP | 166.05% |
| 1999 Q4 | -3.43 Billion GBP | -250.72% |
| 1998 Q2 | 698.69 Million GBP | -64.47% |
| 1998 Q1 | 1.93 Billion GBP | 159.85% |
| 1998 Q4 | -3.04 Billion GBP | -248.07% |
| 1998 FY | - GBP | -4.73% |
| 1998 Q3 | 2.05 Billion GBP | 199.8% |
| 1997 Q4 | -3.22 Billion GBP | -261.17% |
| 1997 Q3 | 2 Billion GBP | -0.5% |
| 1997 Q2 | 2.01 Billion GBP | -1.58% |
| 1997 Q1 | 2.04 Billion GBP | 217.68% |
| 1997 FY | - GBP | -7.79% |
| 1996 Q4 | -1.73 Billion GBP | -169.82% |
| 1996 Q3 | 2.48 Billion GBP | 19.0% |
| 1996 Q1 | 2.12 Billion GBP | 0.0% |
| 1996 FY | - GBP | -18.0% |
| 1996 Q2 | 2.09 Billion GBP | -1.69% |
| 1995 FY | - GBP | 106.07% |
| 1995 Q3 | 1.62 Billion GBP | 148.79% |
| 1995 Q2 | -3.34 Billion GBP | -309.02% |
| 1995 Q1 | 1.59 Billion GBP | -3.17% |
| 1994 FY | - GBP | 10.56% |
| 1994 Q1 | 1.51 Billion GBP | 6.89% |
| 1994 Q2 | -2.46 Billion GBP | -262.18% |
| 1994 Q3 | 1.63 Billion GBP | 166.29% |
| 1994 Q4 | 1.65 Billion GBP | 1.03% |
| 1993 Q3 | 1.39 Billion GBP | 166.17% |
| 1993 Q2 | -2.1 Billion GBP | -239.49% |
| 1993 Q1 | 1.5 Billion GBP | 31.64% |
| 1993 FY | - GBP | 15.65% |
| 1993 Q4 | 1.42 Billion GBP | 2.05% |
| 1992 Q3 | 977.28 Million GBP | 152.27% |
| 1992 Q4 | 1.14 Billion GBP | 17.3% |
| 1992 FY | - GBP | 11.8% |
| 1992 Q1 | 1.11 Billion GBP | 7.51% |
| 1992 Q2 | -1.86 Billion GBP | -266.95% |
| 1991 FY | - GBP | 11.94% |
| 1991 Q1 | 793.32 Million GBP | 10.95% |
| 1991 Q4 | 1.04 Billion GBP | -6.3% |
| 1991 Q3 | 1.11 Billion GBP | 208.78% |
| 1991 Q2 | -1.02 Billion GBP | -228.82% |
| 1990 Q4 | 715 Million GBP | -2.76% |
| 1990 Q1 | 784.13 Million GBP | 4.18% |
| 1990 FY | - GBP | 19.82% |
| 1990 Q2 | -1.02 Billion GBP | -231.2% |
| 1990 Q3 | 735.3 Million GBP | 171.48% |
| 1989 Q3 | 743.77 Million GBP | 199.32% |
| 1989 Q2 | -748.88 Million GBP | -228.72% |
| 1989 Q1 | 581.8 Million GBP | 3.51% |
| 1989 FY | - GBP | 21.49% |
| 1989 Q4 | 752.7 Million GBP | 1.2% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 31.654% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 53.221% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -691.157% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 22976.212% |
| Novartis AG | 19.51 Billion USD | 53.463% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -3052.356% |